News

Title Content Date
Tracing down linear ubiquitination Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. 23.03.2017
M+W Group on a Successful Streak with Semiconductor Awards Leading global high-tech engineering company, M+W Group is celebrating their recent successes in semiconductor projects with awards in both China and Taiwan. 16.03.2017
New leadership at M+W Group Effective 1 March 2017, M+W Group has appointed a new Chief Executive Officer (CEO) and a new Chief Operating Officer (COO). 02.03.2017
Atriva receives seed financing to develop its next generation influenza therapeutic The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), 14.02.2017
CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that the European Commission has appointed CureVac’s CEO, Ingmar Hoerr, Ph.D., as 23.01.2017
Amgen and immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop ne 09.01.2017
Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy CureVac AG today announced that a study with its RNAdjuvant® technology was published in the peer-reviewed journal Cancer Immunology, Immunotherapy. 06.12.2016
CureVac Secures an Additional $29.5 Million From Two New Investors CureVac AG today announced that the company secured a total of $29.5 million in a financing led by new investors Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte (via th 08.11.2016
CureVac Receives Broad Patent for RNAntibody® Technology CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection for the Company’s RNAntibody® technology. 08.11.2016
Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the t 07.11.2016

Pages